Feasibility of Continuous Infusion of Lyophilized Cryoprecipitate in Hemophilia a Patients with Bleeding Episodes
Keywords:
Continuous infusion, Hemophilia, Lyophilized cryoprecipitateAbstract
Abstract: The feasibility of continuous infusion of lyophilized cryoprecipitate (LC) was carried out in five bleeding episodes of four hemophilia A patients (severe 1, moderate 1, mild 2). Their ages ranged from 11 to 18 years. After giving the initial dose of LC within 30 minutes each bottle of LC was additional given by continuous infusion within 4 to 8 hours. As a result, two episodes trom surgenes inchuding explor lap and incision and drainage of an infected hematoma were unevent-fully performed. Another three episodes of thigh muscle bleeding, ileopsoas muscle bleeding and hemarthrosis, and scalp hematoma from head injury were effectively controlled. Moreover, the patients levels of FVIII C were successfully achieved and no adverse effect was found. The utilized LC by the continuous infusion was reduced by 31% as compared to that of bolus injection. In conclusion, the continuous infusion of LC is practical, convenient and cost-effective. It is suggested for hospitalized hemophilia A patients with bleeding episodes.
Downloads
References
Mc Milian CW, Webster WP, Roberts HR, Blythe WB. Continuous intravenous infusion of factor VIII in classic hemophilia. Br J Haemotol 1970;18.659-67.
Hathaway WE, Christian MJ, Clarke SL, Hasiba U. Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia A. Am J Hematol 1984;17:85-8.
Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with hemophilia A. Br J Haemotol 1992;82:729-34.
Schulman S, Varon D, Keller N, Gitel S, Martinowitz U. Monocional purifeid FVIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost 1994;72:403-7.
อำไพวรรณ จวนสัมฤทธิ์, ภัทรพร อิศรางกูร ณ อยุธยา, สมมาตร แก้วโรจน์, ฉัฐยา จิตประไพ, เกษณี คูหาทอง, ผกายมาศ ปิณฑะดิษ, นงนุช สิระชัยนนท์, พงษ์จันทร์ หัตถีรัตน์. ประสิทธิภาพของการให้แฟคเตอร์เข้มข้นด้วยวิธี continuoนs infusion ในผู้ป่วยโรคฮีโมฟีเลีย วารสารโลหิตวิทยาและเวชศาสตร์บริการโลหิต 2541;8:25-32.
Chantanakajornfung A, Isarangkura P, Chuansumrit A, Bunvisuthi P, Pintadit P, Nakdaeng T, Thanthien P,Hathirat P, Nuchprayoon C. Low cost production of heat treated freeze dried cryoprecipitate for treatment of hemophiliacs in Thailand. Haemophilia 1998;4:200.
Chuansumrit A, Isarangkura P, Chantanakajornfung A, Kuhathong K, Pintadit P, Jitpraphai S, Hathirat P, Nuchprayoon C. Efficacy and safety of heat-treated lyophilized cryoprecipitate in hemophilia A. J Med Assoc Thai 19999;82(suppl 1):S57-62.
อำไพวรรณ จวนสัมฤทธิ์. โรคฮีโมฟิเลีย ใน พงษ์จันทร์ หัตถึรัตน์ อำไพวรรณ จวนสัมฤทธิ์, ภัทรพรพร อิศรางกูร ณ อยุธยา, บรรณาธิการ. โลหิตวิทยาในเด็ก. ฉบับพิมพ์ครั้งที่ 3 กรุงเทพฯ:ชัยเจริญ 2538:206-42.
Hardisty RM, Macpherson JC. A one-stage factor VIII (antihemophilic globulin) assay and its use on venous blood and capillary plasma. Thromb Diath Haemorrh 1962;7:215-8.
Rosen S. Assay of factor VIII: C with chromogenic substrate. Scand J Haematol 1984;33:139-45
Kasper CK, Aledort ML, Counts RB, et al. A more uniform measurement of factor VIII inhibitor. Thromb Diath Haemorrh 1975;34:869-72.
Schulman S, Gitel S, Martinowitz U. Stability of factor VIII concentrates after reconstitution. Am J Hematol 1994;45:217-23.
Bona RD, Weinstein A, Weisman SJ, Bartolomeo A, Rickles FR. The use of continuous infusion in the treatment of hemophilia. Am J Hematol 1989;32:8-13.
Mannucci PM, Ruggeri Z.M, Pareti FI, Capitanio A. 1-Deamino-8D-arginine vasopressin: A new pharmacologic approach to the management of hemophilia and von Willebrand's disease. Lancet 1977;1:869-72.
Lowe G, Pettigrew A, Middleton S, et al. DDAVP in hemophilia. Lancet 1977;2:614-5.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
